2-(ethoxycarbonyl)-2-(tert-butoxycarbonyl)indan | 83721-28-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2-(ethoxycarbonyl)-2-(tert-butoxycarbonyl)indan
• 英文别名: indan-2,2-dicarboxylic acid tert-butyl ester ethyl ester；2-O'-tert-butyl 2-O-ethyl 1,3-dihydroindene-2,2-dicarboxylate
• CAS: 83721-28-2
• 化学式: C₁₇H₂₂O₄
• 分子量: 290.359
• InChiKey: HHKOXWUERDVAAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(ethoxycarbonyl)-2-(tert-butoxycarbonyl)indan 在 对甲苯磺酸 作用下， 以 苯 为溶剂， 反应 3.5h， 生成 indan-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  Structure-activity studies of configurationally rigid arylprostaglandins

  摘要：

  Potent, albeit nonselective, smooth-muscle stimulant activity has been previously reported for 16-phenoxy- and 17-phenylprostaglandins, a finding that led to the design and development of the tissue-selective uterine stimulant sulprostone. As an extension of this work, analogues incorporating the 16-phenoxy and 17-phenyl substituents into the rigid indanyl, tetrahydronaphthyl, dihydrobenzofuryl, and dihydrobenzopyranyl ring systems were prepared and evaluated for uterine stimulant activity in vitro and diarrheal effects in vivo. Since these cyclic groups, with the exception of the indanyl, contain a chiral center, both optical antipodes were prepared. These studies demonstrate that ring size, heteroatom, and absolute configuration at C-16 are important determinants for potency and selectivity.

  DOI：

  10.1021/jm00357a004
• 作为产物：
  描述：

  丙二酸叔丁基乙酯 、 1,2-二(溴甲基)苯 在 sodium hydride 作用下， 生成 2-(ethoxycarbonyl)-2-(tert-butoxycarbonyl)indan
  参考文献：
  名称：

  Structure-activity studies of configurationally rigid arylprostaglandins

  摘要：

  Potent, albeit nonselective, smooth-muscle stimulant activity has been previously reported for 16-phenoxy- and 17-phenylprostaglandins, a finding that led to the design and development of the tissue-selective uterine stimulant sulprostone. As an extension of this work, analogues incorporating the 16-phenoxy and 17-phenyl substituents into the rigid indanyl, tetrahydronaphthyl, dihydrobenzofuryl, and dihydrobenzopyranyl ring systems were prepared and evaluated for uterine stimulant activity in vitro and diarrheal effects in vivo. Since these cyclic groups, with the exception of the indanyl, contain a chiral center, both optical antipodes were prepared. These studies demonstrate that ring size, heteroatom, and absolute configuration at C-16 are important determinants for potency and selectivity.

  DOI：

  10.1021/jm00357a004

文献信息

• SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS
  申请人：CAULFIELD Thomas J.

  公开号：US20100113462A1

  公开（公告）日：2010-05-06

  The present invention relates to novel compounds of the formula I: wherein in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.

  本发明涉及公式I的新化合物：其中在其任何立体异构形式或立体异构形式的混合物中以任何比例，或其生理上可接受的盐，其中取代基如此描述。这些创新化合物具有CXCR5抑制活性，特别适用于治疗或预防各种炎症性疾病，例如类风湿性关节炎，多发性硬化症，红斑狼疮，克罗恩病，与人类CXCR5受体调节相关。
• WO2008/151211
  申请人：——

  公开号：——

  公开（公告）日：——
• SPIRO-OXAZOLONES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20170008901A1

  公开（公告）日：2017-01-12

  The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.
• US8569535B2
  申请人：——

  公开号：US8569535B2

  公开（公告）日：2013-10-29
• [EN] SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS<br/>[FR] ACIDES BENZOYLAMINO-INDAN-2-CARBOXYLIQUES SUBSTITUÉS ET COMPOSÉS APPARENTÉS
  申请人：SANOFI AVENTIS

  公开号：WO2008151211A1

  公开（公告）日：2008-12-11

  [EN] The present invention relates to A compound of the formula Ia wherein in any of its stereoisomers forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.
  [FR] La présente invention concerne un composé A de formule Ia sous l'une quelconque de ses formes stéréoisomères ou un mélange de formes stéréoisomères sous un rapport quelconque, ou un sel physiologiquement acceptable de celui-ci, les substituants étant tels que décrits ici. Les composés inventifs ont une activité inhibitrice de CXCR5 et sont particulièrement utiles pour traiter ou prévenir diverses maladies inflammatoires, telles que la polyarthrite rhumatoïde, la sclérose en plaques, le lupus, la maladie de Crohn, associées à la modulation du récepteur de CXCR5 humain.